At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 234 enrolled
Drug / intervention
PTK 0796 +1 moredrug
Likely dose
PTK 0796 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Evaluator-Blinded, Phase 2 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid (Zyvox®) in the Treatment of Adults With Complicated Skin and Skin Structure Infection (cSSSI)
In Brief
A Phase 2 clinical trial evaluating PTK 0796 and Linezolid for Infectious Skin Disease and Bacterial Skin Disease. Completed, enrolled 234 participants across 11 sites.
Detailed Summary
A Phase II trial to demonstrate the safety and efficacy of PTK 0796 in the treatment of complicated skin and skin structure infections (cSSSI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfectious Skin Disease, Bacterial Skin Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
Primary CompletionJan 2008
First PostedOct 2018
TodayJul 2026
First PostedOct 23, 2018
Enrollment StartJul 18, 2007
Primary CompletionJan 7, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.7 years ago
Interventions
PTK 0796drug
PTK 0796 100 mg for injection; PTK 0796 capsule 100 mg
Linezoliddrug
Pre-mixed 600 mg IV infusion solution; Linezolid 600 mg tablets